Travoprost

Glaucoma is the world's leading irreversible blinding eye disease. Among its types, open-angle glaucoma has an insidious course, and most patients have already developed irreversible optic nerve damage at the time of diagnosis. The core of long-term clinical management is to achieve stable reduction of intraocular pressure. Travoprost is an anti-glaucoma drug belonging to the prostaglandin analogue category. By mimicking the effect of natural prostaglandins, it activates FP prostaglandin receptors and increases the outflow efficiency of aqueous humor through the uveoscleral pathway. Compared with traditional β-receptor blockers, it has a higher intraocular pressure lowering amplitude and longer duration of action. A single administration of travoprost can meet the intraocular pressure control needs of most patients with open-angle glaucoma and ocular hypertension, and it has a remarkable advantage in controlling nocturnal intraocular pressure. It is currently a first-line drug recommended by glaucoma diagnosis and treatment guidelines in many countries.

At present, the global market size of anti-glaucoma drugs exceeds 12 billion US dollars, and prostaglandin analogues account for more than 40% of the market, making them the largest segment. With the number of glaucoma patients worldwide exceeding 76 million and the intensification of population aging, the market of travoprost-related preparations maintains a compound annual growth rate of approximately 6%. In the Chinese market, the original research product has long held a dominant position. Since 2019, generic drugs have gradually passed the consistency evaluation and entered the centralized procurement. The winning bid price has dropped by more than 70% compared with the original research product, and the accessibility at the primary level has been greatly improved, driving the annual growth rate of demand for active pharmaceutical ingredients (APIs) to exceed 15%.

The original research enterprise of travoprost is Alcon, and the original brand name is Travatan. The core compound patent of travoprost expired in 2014 in the United States and Europe, and the Chinese compound patent expired in 2013. The main dosage form approved for the original research product is eye drops, with a specification of 2.5ml:0.1mg, which has been included in the Chinese *Catalogue of Reference Preparations for Chemical Drugs* and the FDA Reference Preparation Catalogue. In terms of domestic API registration, a number of enterprises have obtained the API marketing registration number (status A) from the Center for Drug Evaluation (CDE) at present, and a number of domestic enterprises have obtained marketing approval for travoprost eye drops after passing the consistency evaluation. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for travoprost, covering all impurity types involved in the synthesis process and degradation pathways. The products meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day, which can fully support the enterprises' full-process needs for API R&D, quality research and marketing declaration.